For example, studies using non-small cell lung cancer (NSCLC) expressing only the GluR2 subunit indicate that treatment with 2 AMPAR antagonists exerts robust oncolytic activity due to the inhibition of pro-survival kinases such as ERK1/2 and akt [52]. The gene discussed is MAPK3; the disease is non-small cell lung carcinoma.